<DOC>
	<DOCNO>NCT02799355</DOCNO>
	<brief_summary>Of six main genotype hepatitis C virus ( HCV ) , genotypes 2 3 account approximately 30 % chronic infection worldwide . In North India , Genotypes 3 1 account 95 % chronic hepatitis C patient The first three direct-acting antiviral agent receive FDA approval—boceprevir , telaprevir , simeprevir—do currently role treatment genotype 3 infection . In contrast , direct-acting antiviral agent , daclatasvir sofosbuvir , good activity genotype . The SVR rate 90 - 100 % genotype 3 achieve oral sofosbuvir plus ribavirin regimen 24 week . Similar SVR rate achieve Genotype 1 oral sofosbuvir plus weight base ribavirin Pegylated Interferon alpha 2 . However , ongoing discovery development agent directly target various stage HCV replication likely provide HCV-infected patient effective interferon-free therapy . HCV genotype 3 infection associate high incidence hepatic steatosis , rapid progression fibrosis , possibly great risk hepatocellular carcinoma HCV genotype 2 infection.Moreover , patient HCV genotype 3 infection less responsive peginterferon base treatment patient HCV genotype 2 infection .</brief_summary>
	<brief_title>Treatment Chronic Hepatitis With Sofosbuvir Combination With Ribavirin With Without Pegylated Interferon : North India Gastroenterology Consortium</brief_title>
	<detailed_description>Sofosbuvir oral nucleotide analogue inhibitor HCV NS5B polymerase effective HCV genotypes 2 3 administer combination weight base ribavirin 24 week . In Genotype 1 , combination Pegylated Interferon alpha 2 oral Sofosbuvir weight base Ribavirin 12 week result 90 -100 % sustain virological response rate ( SVR ) . These SVR rate chronic hepatitis C genotypes 1,2 3 base Western study . The investigator plan conduct retrospective study Northern India region patient treat Sofosbuvir Ribavirin Sofosbuvir , Ribavirin Peginterferon alpha 2a . The purpose investigator study assess percentage patient sustain virologic response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Age 18 year . Patient treatment either Sofosbuvir Ribavirin ( 24 week ) Sofosbuvir , Ribavirin peginterferon ( 12 week ) . Patient lose follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>